Printer Friendly

LECTEC ANNOUNCES FIRST STOCK DIVIDEND IN COMPANY HISTORY; CITES CONFIDENCE FOR THE FUTURE AND BUSINESS EXPANSION

 LECTEC ANNOUNCES FIRST STOCK DIVIDEND IN COMPANY HISTORY; CITES
 CONFIDENCE FOR THE FUTURE AND BUSINESS EXPANSION
 MINNETONKA, Minn., July 6 /PRNewswire/ -- LecTec Chairman Lee M. Berlin today issued the following statement:
 "We are pleased to announce the first stock dividend in the history of LecTec Corporation (NASDAQ: LECT). Our record of 60 consecutive quarters of profitability and investments in our research ad development area give our people a great sense of optimism and enthusiasm for the company's future.
 During March, our board of directors approved funding to accelerate market introductions of transdermal drug delivery products. Our company has been involved with transdermal technology since 1982 and holds several U.S. and foreign patents for drug dispensing technology based on the use of hydrogels and hydrophobic adhesives.
 A great deal of recent media attention has been focused on nicotine patches. Back in 1988, LecTec produced nicotine patches using our patented drug delivery technology. Based on concerns that a nicotine patch may not be the most effective or safe product for smoking cessation, LecTec researchers sought a safer medication. We announced, in January, an agreement between the University of Minnesota and LecTec to develop a nicotine-free smoking cessation product. A patent for the nicotine-technology has been filed and is pending.
 Fifty million people a year in the U.S. are smokers. The potential market just in the U.S. for smoking cessation products is projected to exceed $1 billion. The market is currently faced with demand far exceeding supply and little product differentiation among the transdermals, all of which contain nicotine as the active ingredients.
 We have been in contact with several prominent partners and expect to announce an alliance to assure expeditious distribution of the future product. We are now positioned to meet volume projections for this growing worldwide market.
 LecTec has completed basic research on adhesive formulations for transdermal systems. Previous projects included medicaments such as nitroglycerin, carazolol, heparin, scopolamine, external analgesics, hydrocortisone, azelastine and nicotine. Our company seeks to research, develop and become the manufacturer of various transdermal drug products in alliances with leading pharmaceutical companies and retail marketers.
 Four LecTec developed and manufactured products have been successfully commercialized. Two of these products were, until August, 1991, sold as prescription items. Since that time, these products have become available as professionally recommended over-the-counter items. Two additional products have since been created and sold on the store shelf. These four products are for the treatment of viral skin infections (warts) and sold under a license agreement by Tsumura Medical. We are in the process of registration and preparation to initiate sales of a pressure sensitive adhesive over-the-counter product containing salicylic acid for the treatment of corns, callouses and bunions.
 Our company practices its concern for the environment by using solvent-free coating technologies and minimizing wastes through the use of recycled, recyclable or biodegradable materials. LecTec's production facilities have been custom designed and adapted for the complete manufacturer of a wide variety of new medical products. We are confident about our company's future."
 LecTec Corporation is pleased to declare today, July 6, 1992, a five (5) percent stock dividend to shareholders of record as of July 16, 1992, to be payable on July 30, 1992.
 LecTec Corporation is a developer, manufacturer and marketer of various skin-related medical products. Among the company's products are cardiac diagnostic and monitoring electrodes, medical tapes and transdermal drug delivery products. LecTec is headquartered in Minnetonka, with an additional facility in Edina, Minn., and is traded on NASDAQ under the symbol LECT.
 -0- 7/6/92
 /CONTACT: Jan Jachimowicz of LecTec, 612-933-2291/
 (LECT) CO: LecTec Corporation ST: Minnesota IN: MTC SU: DIV


AL -- MN003 -- 6547 07/06/92 10:22 EDT
COPYRIGHT 1992 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1992 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Jul 6, 1992
Words:614
Previous Article:DAYTON HUDSON, CHILD CARE GROUPS TO LAUNCH "CHILD CARE AWARE" PUBLIC CAMPAIGN ON CHILD CARE QUALITY
Next Article:CARNEGIE GROUP ANNOUNCES THE AVAILABILITY OF ROCK(TM) 2.1
Topics:


Related Articles
LECTEC BOARD APPROVES ADDED EMPHASIS ON TRANSDERMAL BUSINESS DEVELOPMENT; CITES SIGNIFICANT OPPORTUNITIES
LECTEC ESTABLISHES TECHNICAL AND MARKETING ALLIANCE WITH GERMAN MEDICAL DEVICE COMPANY
LECTEC MAINTAINS SERIES OF PROFITABLE QUARTERS
LECTEC RECEIVES NATIONAL RECOGNITION FOR ENVIRONMENTAL STEWARDSHIP AND INNOVATION
LEICK TO LEAD LECTEC DRUG DELIVERY PRODUCTS EXPANSION
LECTEC THIRD QUARTER RESULTS REFLECT INCREASED INVESTMENT IN NEW PRODUCT DEVELOPMENT
LECTEC ANNOUNCES NEW WOUND CARE PRODUCT
LECTEC RESPONDS TO FDA ADVISORY PANEL INVESTIGATING REPORTS OF ADVERSE REACTIONS OF NICOTINE PATCHES
NATUS AND LECTEC SIGN INVESTMENT AND DEVELOPMENT PACTS
LECTEC AWARDED PATENT FOR NEW BIOACTIVE PRODUCT; SEEKS LICENSING OPPORTUNITIES

Terms of use | Copyright © 2016 Farlex, Inc. | Feedback | For webmasters